Lunai Bioworks Inc.
Lunai Bioworks Inc. is an AI-powered company at the intersection of drug discovery, diagnostics, and biodefense. The company integrates generative AI, proprietary neurotoxicity and chemical datasets, multi-omics, and high-throughput in vivo models to identify and validate therapeutic targets, biomarkers, and to safeguard against dual-use biosecurity risks. Lunai Bioworks partners with academia, industry, and government to advance safe and responsible AI-enabled biomedical innovation, spanning oncology, neurology, precision medicine, and countermeasure development for chemical and biological threats.
Lunai Bioworks Inc.
3400 Cottage Way, Suite G2, #32562, Sacramento, California 95825, USA
What We Do
Integrated system combining multi-omics data, machine learning, generative AI, and in vivo validation to enable target identification and prioritization, risk prediction, and safe compound generation.
Application of AI and phenomic analysis to accelerate the identification of therapeutic targets, drug candidates, and biomarkers.
High-throughput in vivo and AI-driven validation of drug candidates, toxicological profiling, and mechanism-of-action studies.
Strategic research collaborations to co-develop biomarkers, targets, and therapeutics using integrated AI-biology approaches.
Diagnostics
Digital Health Technologies
Show More (1)Drugs
Services
Key People
Chief Executive Officer
Chief Scientific Officer (BioSymetrics subsidiary)
News & Updates
Received a multi-year Small Business Technology Transfer (STTR) grant from NIH to expand the AI-driven translational platform.
Notice of Allowance for computational data harmonization methods for drug discovery and diagnostics.
Study highlighted new prognostic protein biomarkers in Duchenne muscular dystrophy, enabling improved disease monitoring and clinical trial design.
Progress update on AI-driven preclinical biomarker discovery, emphasizing phenogrouping and multimodal analysis in Parkinson's disease.
Usage of AI models and in vivo assay data for rapid detection and mitigation of neurotoxic threats.
Announcement of an AI-based platform for patient stratification, biomarker discovery, and in silico compound screening in neurological diseases.
Partnership providing high-performance computing infrastructure to accelerate biomarker discovery and diagnostics.
Announced the launch of a transformer-based platform embedding biological risk intelligence in generative AI workflows to identify toxic compounds and prevent misuse in hazardous chemical design.
Agreement to jointly develop diagnostics based on platelet RNA signatures, leveraging AI and deep learning for improvements in disease detection and monitoring.
Approved and implemented a 10:1 reverse stock split to comply with Nasdaq minimum bid requirements and streamline capital structure.
Lunai Bioworks announced restoration of compliance with Nasdaq's minimum bid price listing requirement.
Company adopted a new corporate identity with a focus on AI-powered therapeutics and biodefense following a reverse stock split.
Agreement to merge, combining AI-driven drug discovery and biomarker identification expertise.
The companies finalized their merger, forming an integrated entity focused on AI-driven biomarker discovery and precision medicine.
Covers integration and harmonization of biomedical data for predictive analytics in drug discovery.
Patent for feature selection and model optimization in machine learning applied to drug discovery.